Takaya Daisuke, Niwa Hideaki, Mikuni Junko, Nakamura Kana, Handa Noriko, Tanaka Akiko, Yokoyama Shigeyuki, Honma Teruki
RIKEN Center for Biosystems Dynamics Research, 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa, 230-0045, Japan; RIKEN Center for Life Science Technologies, 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, 230-0045, Japan; RIKEN Systems and Structural Biology Center, 1-7-22 Suehiro-cho, Tsurumi, Yokohama, 230-0045, Japan.
RIKEN Systems and Structural Biology Center, 1-7-22 Suehiro-cho, Tsurumi, Yokohama, 230-0045, Japan.
J Mol Graph Model. 2020 Sep;99:107599. doi: 10.1016/j.jmgm.2020.107599. Epub 2020 Apr 10.
CaMKK2 (calcium/calmodulin dependent protein kinase kinase 2) is a serine/threonine protein kinase that regulates phosphorylation of CaM kinases (CaMKs) such as CaMKI, CaMKIV, and AMP-activated protein kinase (AMPK). From a pathological perspective, CaMKK2 plays a role in obesity, diabetes, and prostate cancer. Therefore, CaMKK2 is an attractive target protein for drug design. Here, we tried to find new CaMKK2 inhibitors by using ligand-based and structure-based drug design approaches. From the in silico hit compounds, we identified new inhibitors by using a CaMKK2 kinase assay. We solved X-ray crystallography structures of the CaMKK2-inhibitor complexes and performed Fragment Molecular Orbital (FMO) calculations to analyze the protein-ligand interactions, identify the key residues in inhibitor binding, and quantitatively measure their contribution. We experimentally determined five CaMKK2-inhibitor structures and calculated the binding energies of the inhibitors by the FMO method plus MM-PBSA (Molecular Mechanics Poisson-Boltzmann Surface Area) approach. The results showed a high correlation (R = -0.89) between experimentally measured inhibitory activity (pIC) and the predicted ligand binding energy. We then quantitatively evaluated the contribution of each binding site residue in CaMKK2 by the IFIE (Inter-fragment Interaction Energy)/PIEDA (Pair Interaction Energy Decomposition Analysis) method. The IFIE values indicated that Lys194 and Glu236, which formed hydrogen bonds with the carboxylate groups of the inhibitors, were key residues for ligand binding. PIEDA revealed that the dispersion interaction of inhibitors with hydrophobic residues, such as Ile171, Phe267, and Leu319, contributed highly to ligand binding; we considered that this was due to CH-π interactions with methoxy groups and/or aromatic rings contained in our CaMKK2 inhibitor. These results from the quantitative interaction analysis by the FMO method are useful not only for future CaMMK2 inhibitor development but for application of the FMO method to in silico drug design.
钙调蛋白依赖性蛋白激酶激酶2(CaMKK2)是一种丝氨酸/苏氨酸蛋白激酶,可调节诸如钙调蛋白依赖性蛋白激酶(CaMKs)如CaMKI、CaMKIV和AMP激活的蛋白激酶(AMPK)的磷酸化。从病理学角度来看,CaMKK2在肥胖、糖尿病和前列腺癌中发挥作用。因此,CaMKK2是药物设计中一个有吸引力的靶蛋白。在此,我们尝试通过基于配体和基于结构的药物设计方法来寻找新的CaMKK2抑制剂。从计算机虚拟筛选得到的活性化合物中,我们通过CaMKK2激酶测定法鉴定出新的抑制剂。我们解析了CaMKK2 - 抑制剂复合物的X射线晶体学结构,并进行了片段分子轨道(FMO)计算,以分析蛋白质 - 配体相互作用,确定抑制剂结合中的关键残基,并定量测量它们的贡献。我们通过实验确定了五个CaMKK2 - 抑制剂结构,并通过FMO方法加MM - PBSA(分子力学泊松 - 玻尔兹曼表面积)方法计算了抑制剂的结合能。结果表明,实验测量的抑制活性(pIC)与预测的配体结合能之间存在高度相关性(R = -0.89)。然后,我们通过IFIE(片段间相互作用能)/PIEDA(对相互作用能分解分析)方法定量评估了CaMKK2中每个结合位点残基的贡献。IFIE值表明,与抑制剂羧基形成氢键的Lys194和Glu236是配体结合的关键残基。PIEDA显示,抑制剂与疏水残基(如Ile171、Phe